A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 191-200

  Gras Miralles, Beatriz ^a   Cremonini, Filippo ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Southern Nevada VA Healthcare System   (United States)

Author keywords

Chronic constipation; Irritable bowel syndrome; Opioid induced constipation; Parkinson's disease

Indexed keywords

17 METHYLNALTREXONE; ALUMINUM HYDROXIDE; ALVIMOPAN; ANTIHISTAMINIC AGENT; CALCIUM CARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOCUSATE CALCIUM; DOCUSATE SODIUM; DOPAMINE RECEPTOR STIMULATING AGENT; ISPAGULA; LAXATIVE; LEVODOPA; LINACLOTIDE; LUBIPROSTONE; MACROGOL; METHYLCELLULOSE; MOSAPRIDE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSMOTIC AGENT; PLACEBO; POLYCARBOPHIL CALCIUM; PRUCALOPRIDE; PYRIDOSTIGMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOATING; CLINICAL FEATURE; COMORBIDITY; CONSTIPATION; DIARRHEA; DIET THERAPY; DIETARY FIBER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FLUID INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRANSIT; HUMAN; INTESTINAL DYSMOTILITY; INTESTINE FLUID; IRON THERAPY; IRRITABLE COLON; LIFESTYLE MODIFICATION; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROLOGIC DISEASE; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECRETION (PROCESS); TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

CHRONIC CONSTIPATION; IRRITABLE BOWEL SYNDROME; OPIOID-INDUCED CONSTIPATION; PARKINSON'S DISEASE;

AGED; AGED, 80 AND OVER; AGING; ALPROSTADIL; ANALGESICS, OPIOID; CHRONIC DISEASE; CONSTIPATION; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84873967962     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S30729     Document Type: Review

References (71)

1. Vincent GK, Velkoff VA. The Next Four Decades. The Older Population in the United States: 2010 to 2050. Washington: US Census Bureau; 2010. Available from: http://www.census.gov/prod/2010pubs/p25-1138.pdf. Accessed December 18, 2010.
2. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103(1):170-177.
3. Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther. 2008;28(7):917-930.
4. Talley NJ, Fleming KC, Evans JM, et al. Constipation in an elderly community: a study of prevalence and potential risk factors. Am J Gastroenterol. 1996;91(1):19-25.
5. Wolfsen CR, Barker JC, Mitteness LS. Constipation in the daily lives of frail elderly people. Arch Fam Med. 1993;2(8):853-858.
6. Fukudo S, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. Neurogastroenterol Motil. 2011;23(6):544-e205.
7. Bosshard W, Dreher R, Schnegg JF, Büla CJ. The treatment of chronic constipation in elderly people: an update. Drugs Aging. 2004;21(14):911-930.
8. Mihaylov S, Stark C, McColl E, et al. Stepped treatment of older adults on laxatives. The STOOL trial. Health Technol Assess. 2008; 12(13):iii-iv, ix-139.
9. O'Keefe EA, Talley NJ, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol A Biol Sci Med Sci. 1995;50(4): M184-M189.
10. Rao SS, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging. 2010;5:163-171.
11. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand J Gastroenterol. 1997;32(11):1083-1089.
12. Charach G, Greenstein A, Rabinovich P, Groskopf I, Weintraub M. Alleviating constipation in the elderly improves lower urinary tract symptoms. Gerontology. 2001;47(2):72-76.
13. Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003; 349(14):1360-1368.
14. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice: Fourth National Study: 1991-1992. London: HMSO; 1995.
15. McCrea GL, Miaskowski C, Stotts NA, Macera L, Varma MG. A review of the literature on gender and age differences in the prevalence and characteristics of constipation in North America. J Pain Symptom Manage. 2009;37(4):737-745.
16. Heymen S, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50(4):428-441.
17. Rao SS, Seaton K, Miller M, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol. 2007;5(3):331-338.
18. Camilleri M, Lee JS, Viramontes B, Bharucha AE, Tangalos EG. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc. 2000;48(9):1142-1150.
19. Simón MA, Bueno AM. Behavioural treatment of the dyssynergic defecation in chronically constipated elderly patients: a randomized controlled trial. Appl Psychophysiol Biofeedback. 2009;34(4):273-277.
20. Hanlon JT, Fillenbaum GG, Ruby CM, Gray S, Bohannon A. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging. 2001;18(2):123-131.
21. Stoehr GP, Ganguli M, Seaberg EC, Echement DA, Belle S. Over the-counter medication use in an older rural community: the MoVIES Project. J Am Geriatr Soc. 1997;45(2):158-165.
22. Goh LY, Vitry AI, Semple SJ, Esterman A, Luszcz MA. Self-medication with over-the-counter drugs and complementary medications in South Australia's elderly population. BMC Complement Altern Med. 2009;9:42.
23. Anraku M, Inoue H, Sato E, et al. Surveillance study in collaboration with a university-daycare center for elderly people and nursery school for children on the use of over-the-counter drugs and health food in Fukuyama. Yakugaku Zasshi. 2010;130(8):1093-1103. Japanese.
24. Albert NM, Rathman L, Ross D, et al. Predictors of over-the-counter drug and herbal therapies use in elderly patients with heart failure. J Card Fail. 2009;15(7):600-606.
25. DiPalma JA, Cleveland MB, McGowan J, Herrera JL. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J. 2007;100(11):1085-1090.
26. DiPalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102(7):1436-1441.
27. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138(3):886-895.
28. Mueller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. Randomized double-blind placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in elderly patients with chronic constipation. Gastroenterology. 2008;134(4 Suppl 1):A-157. Abstract 1052.
29. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21(12):1256-e1117.
30. Fleming V, Wade WE. A review of laxative therapies for treatment of chronic constipation in older adults. Am J Geriatr Pharmacother. 2010;8(6):514-550.
31. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11(5):841-850.
32. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G942-G947.
33. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351-1361.
34. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010; 55(4):1090-1097.
35. Suares NC, Ford AC. Efficacy of lubiprostone in the treatment of chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60 Suppl 1:A164-A165. Abstract.
36. Lembo AJ, Johanson JF, Parkman HP, Rao SS, Miner PB Jr., Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci. 2011;56(9):2639-2645.
37. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29(3):329-341.
38. Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012;35(5):587-599.
39. Ueno R, Joswick TR, Wahle A, Zhu Y, Holland PC. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs non-elderly subjects. Gastroenterology. 2006;130(Suppl 2):A189. Abstract S1262.
40. Ueno R, Panas R, Wahle A, Zhu Y, Holland PC. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology. 2006;130 (Suppl 2):A-188. Abstract S1260.
41. Ueno R, Wahle A, Rivera E. Pooled analysis of the most frequent adverse events associated with the use of lubiprostone. Am J Gastroenterol. 2006;101(Suppl 2):S489. Abstract 1264.
42. Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterology. 2007;132:A325. Abstract.
43. Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 3: S224-S232.
44. Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-1654.
45. Krogh K, Christensen P. Neurogenic colorectal and pelvic floor dysfunction. Best Pract Res Clin Gastroenterol. 2009;23(4):531-543.
46. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord. 2009;24(10): 1468-1474.
47. Astarloa R, Mena MA, Sánchez V, de la Vega L, de Yébenes JG. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992;15(5):375-380.
48. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord. 1997;12(6):946-951.
49. Sakakibara R, Yamaguchi T, Uchiyama T, et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord. 2007;22(11):1672-1673.
50. Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;68(6):768-770.
51. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007;22(9):1239-1244.
52. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. JAMA. 1983;249(9):1148.
53. Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease. Mov Disord. 1997;12(3):423-425.
54. Cadeddu F, Bentivoglio AR, Brandara F, Marniga G, Brisinda G, Maria G. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22(10):997-1003.
55. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of opioids in the treatment of chronic non-cancer pain. Pain Physician. 2008;11(Suppl 2):S181-S200.
56. Gianni W, Ceci M, Bustacchini S, et al. Opioids for the treatment of chronic non-cancer pain in older people. Drugs Aging. 2009;26 Suppl 1: S63-S73.
57. van Ojik AL, Jansen PA, Brouwers JR, van Roon EN. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012;29(8):615-625.
58. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16(4):383-394.
59. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3): 372-380.
60. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(Suppl 5A):S11-S18.
61. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137(2):428-440.
62. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554-562.
63. Itawi EA, Savoie LM, Hanna AJ, Apostolides GY. Alvimopan addition to a standard perioperative recovery pathway. JSLS. 2011;15(4): 492-498.
64. Sawh SB, Selvaraj IP, Danga A, Cotton AL, Moss J, Patel PB. Use of methylnaltrexone for the treatment of opioid-induced constipation in critical care patients. Mayo Clin Proc. 2012;87(3):255-259.
65. Gatti A, Sabato AF. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clin Drug Investig. 2012; 32(5):293-301.
66. Fei G, Raehal K, Liu S, et al. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther. 2010;334(1):333-340.
67. Sun X, Wang X, Wang GD, et al. Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci. 2011;56(2):330-338.
68. Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomised, double-blind, placebo controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic non-cancer pain. Gastroenterology. 2010;138 Suppl 1:S-129. Abstract 906.
69. Jamal M, Mareya S, Woldegeorgis F, Joswick T, Ueno R. Lubipro stone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non cancer pain: Results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Gastroenterology. 2012;142(5 Suppl 1): S144-S145. Abstract 848a.
70. Sucampo Pharmaceuticals. Takeda and Sucampo report top-line results of two phase 3 trials of lubiprostone in opioid-induced bowel dysfunction [press release]. Bethesda, MD: Sucampo Pharmaceuticals Inc; 2009 [Jul 21]. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1309679&highlight=.2009. Accessed December 18, 2012.
71. Sucampo Pharmaceuticals. Positive top-line results from phase 3 long-term, open-label safety and efficacy trial of lubiprostone in opioid-induced bowel dysfunction patients [press release]. Bethesda, MD: Sucampo Pharmaceuticals; 2012 [Apr 5]. Available from: http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-newsArticle&ID=1680449&highlight=.2012. Accessed December 18, 2012.